SISTER

/

SISTER is a phase-2, prospective, randomized, placebo-controlled, blinded, dose-finding trial that aims to determine the safety and preliminary efficacy of TS23. TS23 is a monoclonal antibody against the alpha-2 antiplasmin (α2-AP), in acute ischemic stroke.

The study will be conducted at up to 50 U.S. sites and enroll 300 adults (>18 years) with acute ischemic stroke who have a baseline NIHSS >6 and are able to receive study drug within 4.5-24 hours after stroke onset (or last known well) who have evidence of core-penumbra mismatch on baseline perfusion imaging and are not planned for endovascular intervention or standard of care intravenous (IV) thrombolysis.

TESTED

/

The overall goal of the TESTED study, we will compare the risks and benefits of EVT to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.

DOCUMENTS:

Inclusion Exclusion Criteria

INFORMED CONSENT:

Informed Consent - Participant

Informed Consent - Caregiver

MISC:

Website

FASTEST

/

The objective of the FASTEST Trial is to establish the first treatment for acute spontaneous ICH within a time window and subgroup of patients that is most likely to benefit. Hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of participants most likely to benefit, will improve outcomes at 180 days as measured by the mRS and decrease ongoing bleeding as compared to standard therapy.

ENDOLOW

/
 
 

This study will test the hypothesis that patients presenting within 8 hours of onset with cerebral ischemia in the setting of proximal LVO and low baseline NIHSS scores (0-5) will have better 90-day clinical outcomes (mRS distribution) with immediate mechanical thrombectomy (iMT) compared to initial medical management (iMM).

DOCUMENTS:

Inclusion Exclusion criteria

Flowsheet

INFORMED CONSENT:

Informed Consent

MISC:

ENDOLOW Website

 

MOST

/

The goal of this study is to determine the effectiveness of combining tPA with blood thinners argatroban or eptifibatide. The research will look at whether combining tPA with either argatroban or eptifibatide will produce better results in stroke patients in the first 90 days after suffering a stroke versus tPA with a placebo.